CAI Caris Life Sciences, Inc.
Debt Financing ·
Caris Life Sciences took a $400,000,000 term loan from funds managed by Blue Owl and Blackstone to repay its 2023 credit agreement. The new deal also adds a $300,000,000 delayed draw facility for acquisitions, and the company already reported $796.3 million of cash at the end of 2025.
We have not published a story on Caris Life Sciences yet. When there is news, it will appear here.
Caris Life Sciences describes itself as a next-generation AI TechBio company and precision medicine pioneer, founded in 2008. It develops and commercializes molecular profiling solutions and uses artificial intelligence and machine learning, with an initial focus on oncology. Its Molecular Intelligence portfolio includes the MI Profile platform for tissue-based whole exome and whole transcriptome sequencing, the Caris Assure platform for blood-based profiling, and the Precision Whole Genome platform, with a whole genome sequencing launch anticipated in 2026. The company says it has performed sequencing on over 1,000,000 cases and has built a multi-modal clinico-genomic dataset covering the cancer care continuum, including early detection, minimal residual disease tracking, therapy selection and treatment monitoring. Its Caris Discovery pillar uses the data and AI to find drug targets for antibody-directed therapies, small molecules, protein degradation and cell therapy. Named biopharma partners include Moderna, AbbVie, Xencor, Merck KGaA and Genentech. The company also works with the Caris Precision Oncology Alliance, a network of cancer centers and research consortia.
| Product or program | What it is | Stage |
|---|---|---|
| MI Profile Platform | Tissue-based whole exome and whole transcriptome molecular profiling | |
| Caris Assure Platform | Blood-based whole exome and whole transcriptome molecular profiling | |
| Precision Whole Genome Platform | Blood and tissue whole genome sequencing | launch anticipated in 2026 |
| Caris Discovery | AI-driven discovery of drug targets across several modalities |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $812.0 million | $412.3 million |
| Research and development | $101.6 million | $113.9 million |
| Net income (loss) | -$68.1 million | -$281.9 million |
| Cash from operations | $83.2 million | -$245.2 million |
| Cash and equivalents | $796.3 million | $64.0 million |
| Short-term investments | $2.3 million | $2.2 million |
Caris Life Sciences, Inc. trades under the ticker CAI on NASDAQ.
Caris Life Sciences, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:49J; FWB:49J; GETTEX:49J; HAM:49J; HAN:49J; LS:A41A14; LSX:A41A14; MUN:49J; SWB:49J; TRADEGATE:49J; XETR:49J.
The SEC Central Index Key (CIK) for Caris Life Sciences, Inc. is 2019410. Its filings are on SEC EDGAR.
282,595,186 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Caris Life Sciences, Inc. under United States.
Our directory classifies Caris Life Sciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Caris Life Sciences, Inc. is US1421521071.
aibio.space lists Caris Life Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as TX.
Caris Life Sciences describes itself as a next-generation AI TechBio company and precision medicine pioneer, founded in 2008. It develops and commercializes molecular profiling solutions and uses artificial intelligence and machine learning, with an initial focus on oncology.
MI Profile Platform: Tissue-based whole exome and whole transcriptome molecular profiling
Caris Assure Platform: Blood-based whole exome and whole transcriptome molecular profiling
$812.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Caris Life Sciences, Inc. reported a net loss of $68.1 million for the fiscal year ended Dec 31, 2025, and generated $83.2 million of cash from operations, per its annual report to the SEC.
$101.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio